External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease

Infliximab is approved for treatment of various chronic inflammatory diseases including inflammatory bowel disease (IBD). However, high variability in infliximab trough levels has been associated with diverse response rates. Model-informed precision dosing (MIPD) with population pharmacokinetic mode...

Descripción completa

Detalles Bibliográficos
Autores principales: Schräpel, Christina, Kovar, Lukas, Selzer, Dominik, Hofmann, Ute, Tran, Florian, Reinisch, Walter, Schwab, Matthias, Lehr, Thorsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468301/
https://www.ncbi.nlm.nih.gov/pubmed/34575443
http://dx.doi.org/10.3390/pharmaceutics13091368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468301/
https://www.ncbi.nlm.nih.gov/pubmed/34575443
http://dx.doi.org/10.3390/pharmaceutics13091368

Ejemplares similares